Molecule intelOpportunity: ModerateEssential

Sumatriptan

44 brands · 27 companies · product forms

ATC: N02CC01

Opportunity snapshot

Launch attractiveness
41
Market saturation
72
Price room
100
Regulatory risk
0
44
brands
27
companies
Rs 682.83
median price
35
price points
10.8x
price spread
100
confidence %

Who competes here

Top companies by brand count — fragmented market (no dominant player) · leader share 7%

Price room

Across observed sources and strengths
CheapestRs 180.08
MedianRs 682.83
Most expensiveRs 1,944.97
Spread10.8×
Sources: DRAP-official, DVAGO, Servaid

max/min price ratio 10.80x across 35 trusted points (Rs 180.08-1944.97). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Brands & products on the market

Sample of 12 live products for Sumatriptan — each links to its own medicine page.

Why this score

Launch attractiveness

40% supply-gap(25) + 25% price-variation(100) + 20% low-competition(28) + 15% supply-disruption(0), damped by confidence(100). Higher = more attractive, less crowded opportunity.

Market saturation

27 canonical companies and 44 brands compete (saturation pegged at 30 companies / 150 brands).

Price room

max/min price ratio 10.80x across 35 trusted points (Rs 180.08-1944.97). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Regulatory risk

No DRAP alerts on this molecule's brands.

Confidence

Full coverage.

Packaged brief for this moderate opportunity?

Molecule page + company profiles + price-room analysis are the pilot package for pharma teams.

See packaged reports All 3868 molecules

Molecule intelligence as of 2026-07-30. Brand/company counts from DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.